Predict your next investment

OncoResponse company logo
Corporation
HEALTHCARE | Biotechnology
oncoresponseinc.com

See what CB Insights has to offer

Total Raised

$103.1M

Investors Count

16

Deal Terms

4

OncoResponse Funding, OncoResponse Valuation & OncoResponse Revenue

7 Fundings

OncoResponse's latest funding round was a Series C for $40.6M on March 31, 2021.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

3/31/2021

Series C

$40.6M

$0.00B

((9.99x))

FY 1234

3

9/6/2018

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

3/9/2017

Series A - IV

$99M

$0.00B

((9.99x))

FY 1234

10

10/10/2016

Series A - III

$99M

$0.00B

((9.99x))

FY 1234

10

5/26/2016

Series A - II

$99M

$0.00B

((9.99x))

FY 1234

10

Date

3/31/2021

9/6/2018

3/9/2017

10/10/2016

5/26/2016

Round

Series C

Series B

Series A - IV

Series A - III

Series A - II

Amount

$40.6M

$99M

$99M

$99M

$99M

Investors

Valuation

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

3

10

10

10

10

OncoResponse Deal Terms

4 Deal Terms

OncoResponse's deal structure is available for 4 funding rounds, including their Series B from September 06, 2018.

Round

Series B

Series A - III

Series A - II

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

$99M

Dividend Rate

$99M

$99M

$99M

Liquidation Preferences

$99M

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

$99M

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A - III

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A - II

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

OncoResponse Investors

16 Investors

OncoResponse has 16 investors. ARCH Venture Partners invested in OncoResponse's Series C funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/6/2015

3/31/2021

3
Series A, Series B (2018), Series C (2021)

Venture Capital

Illinois

10/10/2016

3/31/2021

3
Series A - III, Series B (2018), Series C (2021)

Corporate Venture

Monaco

10/6/2015

3/31/2021

3
Series A, Series B (2018), Series C (2021)

Venture Capital

California

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Venture Capital

Missouri

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sovereign Wealth Fund

Qatar

First funding

10/6/2015

10/10/2016

10/6/2015

00/00/0000

00/00/0000

Last Funding

3/31/2021

3/31/2021

3/31/2021

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Rounds

3
Series A, Series B (2018), Series C (2021)
3
Series A - III, Series B (2018), Series C (2021)
3
Series A, Series B (2018), Series C (2021)

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Corporate Venture

Venture Capital

Venture Capital

Sovereign Wealth Fund

Location

Illinois

Monaco

California

Missouri

Qatar

OncoResponse Acquisitions

1 Acquisition

OncoResponse acquired 1 company. Their latest acquisition was Paganini Biopharma on November 07, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/7/2017

Acquired

1

Date

11/7/2017

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.